Literature DB >> 23956113

Outpatient management of vascular access devices in children receiving radiotherapy: complications and morbidity.

Jennifer Bratton1, Peter A S Johnstone, Kevin P McMullen.   

Abstract

BACKGROUND: When treating children with cancer, long-term venous access is critical. This is especially true in the context of children receiving daily radiation therapy (RT) under general anesthesia. We have previously reported <0.1% risk of complications in complications in over 4,040 pediatric treatments under general anesthesia in our outpatient facility. Here, we present our experience with venous catheter access techniques in children receiving daily proton RT. PROCEDURE: After Institutional Review Board approval, we reviewed our center's records between September 9, 2004 and October 23, 2012 with respect to complications and morbidity of indwelling catheters in our pediatric patients.
RESULTS: Vascular access device (VAD) types included: 110 patients with indwelling port-a-cath (PAC), 34 PICC line devices, and 34 central venous catheter (CVC) devices in 170 patients. Median catheter life during RT was 43 days (range 1-86 days) with a total of 7,169 total catheter days while patients received RT. A 14% PAC complication rate included negative blood return (6.3%) and infection (3.6%). Complication rates for PICC and CVC access devices were 38% and 20.5%, respectively (χ(2) P = 0.007 when compared with PAC). Most frequent complications for PICC lines were no blood return (11.7%), and infection or occlusion (8.8% each). CVC complications were breakage (8.8%) and infection (8.8%). Access device replacement rates were 3.6% (PAC), 14.7% (PICC), and 8.8% (CVC).
CONCLUSIONS: In the outpatient delivery of RT to children, indwelling ports provide greater convenience, less likelihood of infection or complication, and greater durability than PICC or CVC devices.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  pediatric oncology; proton therapy; radiotherapy; vascular access devices

Mesh:

Year:  2013        PMID: 23956113     DOI: 10.1002/pbc.24642

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

Review 1.  A Review on Pharmacological Properties of Zingerone (4-(4-Hydroxy-3-methoxyphenyl)-2-butanone).

Authors:  Bilal Ahmad; Muneeb U Rehman; Insha Amin; Ahmad Arif; Saiema Rasool; Showkat Ahmad Bhat; Insha Afzal; Ishraq Hussain; Sheikh Bilal; Manzoor ur Rahman Mir
Journal:  ScientificWorldJournal       Date:  2015-05-27

2.  Parameters of anesthesia/sedation in children receiving radiotherapy.

Authors:  Kevin P McMullen; Tara Hanson; Jennifer Bratton; Peter A S Johnstone
Journal:  Radiat Oncol       Date:  2015-03-11       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.